Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldoxorubicin - NantCell

Drug Profile

Aldoxorubicin - NantCell

Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - CytRx Corporation

Latest Information Update: 11 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KTB Tumorforschungs
  • Developer CytRx Corporation; NantCell
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Hydrazines; Maleimides; Pyrroles; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Soft tissue sarcoma; Ovarian cancer; Pancreatic cancer; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Chondrosarcoma; Colorectal cancer; Osteosarcoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 23 Aug 2019 NantKwest withdraws the phase II QUILT-3.088 trial prior to enrolment for Pancreatic Cancer (Metastatic disease, First-line therapy) as the trial was not initiated in USA (NCT03563144)
  • 26 Jun 2019 CytRx Corporation receives a patent from the US Patent and Trademark Office (USPTO) covering the formulation, storage, delivery and administration of aldoxorubicin at room temperature
  • 31 May 2019 Efficacy and safety data from the phase Ib/II QUILT-3.067 trial in Triple negative breast cancer presented at the 55th Annual Meeting of American Society of Clinical Oncology (ASCO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top